Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials

Vanessa N Raabe; Jennifer Lighter; Arthur L Caplan; Adam J Ratner

doi:10.1093/cid/ciaa656

Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials

Clin Infect Dis. 2020 Dec 15;71(12):3248-3249. doi: 10.1093/cid/ciaa656.

Authors

Vanessa N Raabe^{1

2}, Jennifer Lighter¹, Arthur L Caplan³, Adam J Ratner^{1

4}

Affiliations

¹ Department of Pediatrics, Division of Pediatric Infectious Diseases, New York University Grossman School of Medicine, New York, New York, USA.
² Department of Medicine, Division of Infectious Diseases and Immunology, New York University Grossman School of Medicine and NYU Langone Vaccine Center, New York, New York, USA.
³ Department of Population Health, Division of Bioethics, New York University Grossman School of Medicine, New York, New York, USA.
⁴ Department of Microbiology, New York University Grossman School of Medicine, New York, New York, USA.

Abstract

Pediatric patients are excluded from most coronavirus disease 2019 (COVID-19) therapeutic trials. We outline a rationale for the inclusion of children in COVID-19 therapeutic trials, which enabled us to include children of all ages in a therapeutic COVID-19 trial at our institution.

Keywords: COVID-19; SARS-CoV-2; clinical trial; ethics; pediatrics.

MeSH terms

Adolescent
COVID-19 Drug Treatment*
COVID-19 Serotherapy
COVID-19* / therapy
Child
Clinical Trials as Topic*
Coronavirus Infections*
Humans
Immunization, Passive
SARS-CoV-2
United States